DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually.
It is a $11.4B healthcare company. Revenue grew 6.4% over the last year, it keeps 6¢ of every dollar of sales as profit, and its net debt equals ~5.9 years of free cash flow. It trades at 13.5× earnings — around the middle of its own history.
- Website
- davita.com
- Location
- Denver, CO
- Employees
- 78 000
- Sector
- Healthcare
- Founded
- 1979
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation and quality; Growth and Health lag behind.
Valuation87
- P/E vs own history46th pct · 12/25
- FCF yield14.1% · 25/25
- P/S0.8x · 25/25
- EV/EBITDA7.6x · 25/25
Growth30
- Revenue CAGR4.1% · 6/25
- Net income CAGR-6.5% · 0/25
- EPS CAGR ~5Y9.3% · 12/25
- Fwd implied growth11.6% · 12/25
Profitability70
- ROIC8.4% · 12/25
- ROE181.2% · 25/25
- Net margin6.0% · 13/25
- Operating margin15.1% · 20/25
Health22
- Altman Zn/a · 0/25
- Current ratio1.47 · 12/25
- Interest coverage3.5x · 10/25
- Net cash / debtD/A 55% · 0/25
Quality90
- Piotroski F6/9 · 15/25
- Beneish M-2.69 · 25/25
- FCF conversion190% · 25/25
- Margin stabilityσ 2.7% · 25/25
Moat50
- ROIC >12% years6/10 yrs · 13/25
- Median gross margin14.6% · 0/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 1.4% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2021FinancialBest year on record$978M net income
- 2017AcquisitionIt acquired WellHealth Quality Care
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $10B$14.7B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2016AcquisitionIt acquired the Everett Clinic Medical Group, a 20-site physicians practice with 315,000 patients in…
- 2014AcquisitionDaVita acquired Colorado Springs Health Partners, with 600 employees and 110,000 patients
- 2012AcquisitionDaVita acquired Healthcare Partners for $4.42 billion
- 2005AcquisitionThe company acquired Gambro Healthcare
- 2000MilestoneThe company was renamed DaVita Inc
- Feb 27, 1998AcquisitionThe company acquired Renal Treatment Centers for $1.3 billion in stock
- 1995IPOThe company became a public company via an initial public offering, raising $107 million
- 1994Acquisition70% of the company was acquired by DLJ Merchant Banking Partners in a leveraged buyout for $75.5…
- 1979FoundedThe company was founded in 1979 as Medical Ambulatory Care, Inc., a subsidiary of National Medical Enterprises, Inc
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
No standout strengths in the available data.
Watch-outs
- Net debt equals ~5.9 years of free cash flow
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+6.4% YoY
- Profitable — makes more than it spends$847M TTM
- Profit growing — earnings are higher than last year+19.1% YoY
- Generates cash — cash left after running and investing$1.61B TTM
- Debt under control — could handle its obligations~5.9y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$11.4B market cap
- Not printing shares — share count not ballooning — you keep your slice-38.1% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 22/100
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 13.5
Peer comparisonDaVita Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| DVA this company | $11.4B | 13.5 | +6.4% | 6.0% | Strained |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: DVA vs LLY · DVA vs JNJ · DVA vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/DVA
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of DVA on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $179.25 · market cap $11.4B.